Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Anti-HER2 Therapy in Elderly Breast Cancer Patients

Author(s): Masataka Sawaki

Volume 9, Issue 4, 2014

Page: [263 - 266] Pages: 4

DOI: 10.2174/1574887109666141127102035

Price: $65

Abstract

Targeting anti-HER-2 therapy, trastuzumab, Lapatinib, T-DM1, and Pertuzumab is a standard therapy for HER-2-overexpressing breast cancer. But there are less data available related to anti-HER-2 therapy in elderly patients because they have been consistently underrepresented in clinical trials. Anti- HER-2 therapy among an elderly population was reviewed including approaches for making treatment effective.

Keywords: Anti-HER2 therapy, breast cancer, HER-2/neu, elderly.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy